West Pharmaceutical Services Inc. disclosed a credit agreement in an Oct. 26 Form 8-K filed with the U.S. Securities and Exchange Commission, which also records the end of an earlier agreement and a direct financial obligation.
The filing index lists Items 1.01, 1.02 and 2.03, covering a material agreement, the end of a prior agreement and a direct financial obligation. It also lists the agreement as Exhibit 10.1.
West’s second-quarter 2026 Form 10-Q said the company had no borrowings on its $500 million multi-currency revolving line as of June 30. West reported $497.7 million available after accounting for $2.3 million in letters of credit.
West’s 2025 annual report said the revolving line was scheduled to expire in March 2027. The company’s calendar lists its third-quarter 2026 conference call for Thursday, Oct. 29, at 8 a.m. ET.
